InsidersTradesSigma
Track the BIODESIX INC stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, BIODESIX INC has logged 203 public disclosures. Market capitalisation: €256.5m. The latest transaction was filed on 13 August 2026 (Acquisition). Among the most active insiders: SCHULER JACK W. Every trade is accessible without an account.
203
Insider Decl.
n/a
Thresholds
€57m
60 ops.
Buy Volume
€13,668
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BIODESIX INC Strong Buy (bullish), based on 6 analysts. Average price target: US$34.00.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,741 of 29,056 companies
32.0
score / 100
Value16
Quality48
FCF yld-8.4%
Earn yld-12%
EV/EBITDA·
ROE·
Gross mgn81%
Net mgn-40%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 August 2026
Declarations203 total
15,000 shares@ US$24.4661Common StockSEC:0000905148-26-003641:0
Canonical exit: 10 Nov 2026 (T+90)
13,900 shares@ US$24.24670.13% mcap0.6% of flowCommon StockSEC:0000905148-26-003599:0
Canonical exit: 8 Nov 2026 (T+90)
13,700 shares@ US$24.00810.13% mcap0.6% of flowCommon StockSEC:0000905148-26-003599:1
Canonical exit: 9 Nov 2026 (T+90)
1,361 sharesCommon StockSEC:0000905148-26-003146:0
1,361 sharesCommon StockSEC:0000905148-26-001495:0
563 sharesCommon StockSEC:0000905148-26-000990:0
1,469 sharesCommon StockSEC:0000905148-26-000989:0
4,844 sharesCommon StockSEC:0000905148-26-000988:0
1,528 sharesCommon StockSEC:0000905148-26-000987:0
1,469 sharesCommon StockSEC:0000905148-26-000986:0
2,584 sharesCommon StockSEC:0000905148-26-000637:0
263 sharesCommon StockSEC:0000905148-26-000636:0
1,600 sharesCommon StockSEC:0000905148-26-000635:0
1,481 sharesCommon StockSEC:0000905148-26-000634:0
9,998 sharesCommon StockSEC:0000905148-26-000633:0
80,000 shares@ US$11.80841.1% of flowCommon StockSEC:0000905148-26-000362:0
Canonical exit: 23 Apr 2026 (T+90)
20,000 shares@ US$11.80320.3% of flowCommon StockSEC:0000905148-26-000362:1
Canonical exit: 26 Apr 2026 (T+90)
82,465 shares@ US$10.95691.4% of flowCommon StockSEC:0000905148-26-000331:0
Canonical exit: 22 Apr 2026 (T+90)
805 sharesCommon StockSEC:0000905148-26-000249:0
298 shares@ US$8.14934.6% of flowCommon StockSEC:0000905148-26-000249:1
2,633 sharesCommon StockSEC:0000905148-26-000250:0
970 shares@ US$8.14933.7% of flowCommon StockSEC:0000905148-26-000250:1
805 sharesCommon StockSEC:0000905148-26-000251:0
298 shares@ US$8.149313.0% of flowCommon StockSEC:0000905148-26-000251:1
805 sharesCommon StockSEC:0000905148-26-000252:0
25 of 203 declarations
关于 BIODESIX INC
Biodesix, Inc.（股票代码BDSX）是一家总部位于美国的精准诊断公司，在美国纳斯达克上市，专注于肺部疾病，特别是胸部肿瘤领域。Biodesix成立于2006年，总部位于科罗拉多州路易斯维尔，在肺癌和肺结节管理方面的临床决策支持领域建立了利基市场地位。其公司总部和主要实验室位于919 W Dillon Road, Louisville, CO 80027。 该公司的商业模式围绕两个互补的支柱。首先，Biodesix商业化专有诊断测试，特别是Nodify Lung和IQLung品牌。Nodify Lung旨在帮助临床医生评估肺结节的恶性风险，利用血液生物标志物，支持更早、更明智的护理途径。IQLung是针对非小细胞肺癌患者的治疗指导组合，结合了肿瘤分析和免疫分析工具。其次，该公司利用其科学、技术和运营能力，为生物制药、生命科学和研究客户提供开发服务，以支持诊断和治疗开发项目。 从竞争角度来看，Biodesix在一个高度专业化但具有吸引力的诊断市场中运营，其中临床效用、报销、周转时间和与医生工作流程的整合至关重要。该公司强调经过临床验证的测试和多项Medicare覆盖的服务，这有助于在证据和报销具有决定性作用的市场中推广。其差异化根植于肺部疾病的深厚专业知识，而非广泛的通用诊断平台。 从地理上看，该业务主要以美国为中心，与其总部、商业足迹和报销驱动模式相符。公司近期沟通表明2025年势头有所改善，收入增长得益于诊断测试和开发服务。Biodesix还强调了支持Nodify Lung的新临床和经济数据，以及Thermo Fisher Scientific对其NGS诊断卓越中心的认可，这有助于增强其技术平台的可信度。 对于法语投资者而言，Biodesix最好被视为一家在纳斯达克上市的专业医疗保健股票，其增长潜力与执行力、报销动态以及其肺癌诊断产品组合的更广泛采用相关。
